Bone mineral density after two years of treatment with relugolix combination therapy and one-year post-treatment follow-up in women with endometriosis: spirit program

To evaluate bone mineral density (BMD) changes in women with endometriosis (EM)-associated pain treated with relugolix combination therapy (Rel-CT: relugolix 40 mg, estradiol 1 mg and norethindrone acetate 0.5 mg) in the SPIRIT long-term extension (LTE) study through 104 weeks and post-treatment follow-up (PTFU) for 12 months.

https://www.fertstert.org/article/S0015-0282(23)00995-0/fulltext?rss=yes

Source: Fertility and Sterility - October 1, 2023 Category: Reproduction Medicine Authors: Michael R. McClung, Neil Johnson, Steven R. Cummings, Serge L. Ferrari, Julie S. Perry, Yi Zhong, Rachel B. Wagman Source Type: research